VitaVitro Biotech closes Series B financing round

Shenzhen-based VitaVitro Biotech announced that it has completed the Series B round of financing jointly invested by Dalton Ventures and Weilai Zhuoshi. Proceeds from this round of financing will mainly be used for R&D and channel expansion.

Shenzhen-based VitaVitro Biotech announced that it has completed the Series B round of financing jointly invested by Dalton Ventures and Weilai Zhuoshi. Proceeds from this round of financing will mainly be used for R&D and channel expansion.

VitaVitro Biotech was established in 2015, headquartered in Shenzhen. The company is committed to providing advanced technologies for assisted reproduction industry and integrated solutions for global assisted reproduction laboratories; VitaVitro’s product portfolio covers the entire process of assisted reproduction from egg retrieval, cryopreservation, culture to transfer.

The company operates in Europe, Americas, Asia Pacific and other regions.

In 2017, VitaVitro Biotech began to expand the international market with a new brand, and its main products are leading and differentiated in research and development and technology.

The two products vitrified freezing liquid and vitrified thawing liquid developed by the company are the first Chinese products that have obtained the FDA 510 (K) certification of the United States, and have been sold in the United States for two years.

Since the launch of the first product in 2018,VitaVitro Biotech has basically maintained two to three new product approvals per year, and currently can provide a full range of products for embryo laboratory overseas.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/06/14/vitavitro-biotech-closes-series-b-financing-round/.

Leave a Reply

Please Login to Comment